- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metab, QN, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C, RNA, Quantitative, PCR
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Metanephrines, Fractionated, Free, LC/MS/MS, PlasmaTest code(s) 19548
This is an outdated version of this FAQ. It was effective 04/20/2012 to 12/28/2014.
The current version is available here.
Question 1. Why are there so many different tests used for the diagnosis of pheochromocytoma? Which one is the best?
Both plasma metanephrines and plasma catecholamines have been used for the diagnosis of pheochromocytoma. If plasma metanephrines and/or catecholamines are not available, then the next best test is urinary fractionated metanephrines and/or catecholamines.
The 24-hour urine tests for metanephrines and catecholamines remain useful screening tests for pheochromocytoma, based on data from some research groups showing good diagnostic specificity of urine testing.1 The urine specimen requires a complete 24-hour collection and an acid preservative must be added to the collection container.
Urinary VMA is no longer used as a diagnostic test for pheochromocytoma. However, urinary VMA can be used in conjunction with urinary HVA for the diagosis of neuroblastoma.
Question 2. What are the advantages and potential disadvantages of the plasma metanephrine test over the standard urine tests for pheochromocytoma?
There are considerable data showing that the plasma metanephrines test is more sensitive than urinary metanephrines and/or catecholamines, likely because even small pheochromocytomas may continually leak metanephrines even if they are not actively secreting catecholamines. Another consideration is practicality, in that a 24-hour urinary collection can be difficult for some patients. A potential disadvantage of the plasma metanephrines test is that it requires additional patient preparation (at least 20 minutes of rest prior to blood draw, preferably in a reclining or seated position with a butterfly or indwelling blood drawing catheter in place). Also, because plasma metanephrine levels are affected by acute stress, patients in whom blood drawing generates great anxiety (e.g., children) may be more likely to have mildly elevated levels from stress alone. A normal result for plasma metanephrines is strong evidence against the diagnosis except in early pre-clinical disease.
Question 3. What is the clinical sensitivity and specificity of the plasma metanephrines test?
Sensitivity for plasma metanephrines is 96% to 99% and the specificity is 79% to 89%.1
Question 4. What is the definition and clinical significance of borderline plasma metanephrines?
Plasma metanephrine and/or normetanephrine levels ≥4-fold the upper limits of the reference ranges are strongly suggestive of a pheochromocytoma.2 Levels between 1 and 4-fold elevated are considered borderline and are significant, but not diagnostic, and may be due to medications (see Question 6 below) or stress.
The standard protocol to minimize stress during sample collection stipulates that the patient should be reclining for 20 minutes with an IV inserted before withdrawing the specimen from the IV. Patient should also refrain from alcohol and tobacco for 12 hours.
Question 5. Which test(s) should be ordered to verify borderline elevated plasma metanephrines?
24-hour urine for metanephrines should be ordered. Chromogranin A levels are elevated in most patients with pheochromocytoma; however, the test is not specific and is seen in other disorders such as carcinoid.
Question 6. Which drugs can cause false-positive elevations of plasma metanephrine and/or normetanephrine?
Drugs that may cause false-positive elevations of plasma metanephrine and/or normetanephrine include: tricyclic antidepressants, alpha-blockers, beta-blockers, monoamine oxidase inhibitors, sympathomimetics, and stimulants. It is important that patients abstain from these medications preferably for 1-2 weeks prior to sample collection.
Question 7. Should plasma metanephrines be performed if the results are negative in the 24-hour urine catecholamines test?
If clinical suspicion remains high, and especially if symptoms are episodic, plasma metanephrines should be measured due to their high diagnostic sensitivity. The 24-hour urine tests are not always successful in detecting intermittently secreting tumors.
- Kudva YC, Sawka AM, Young WF. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic Experience. J Clin Endocrinol Metab. 2003; 88: 4533-4539
- Algeciras-Schimnich A, Preissner CM, Young WF Jr, et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab. 2008;93:91-95.
Document FAQS.38 Revision: 0